Free PSA Test Awarded US Patent

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

ABBOTT PARK, Ill--Abbott Laboratories and the Finnish-based company Wallac Oy, a subsidiary of EG&G Inc. (Wellesley, Mass), have received a US patent for two methods of assaying free PSA (prostate-specific antigen).

ABBOTT PARK, Ill--Abbott Laboratories and the Finnish-based companyWallac Oy, a subsidiary of EG&G Inc. (Wellesley, Mass), havereceived a US patent for two methods of assaying free PSA (prostate-specificantigen).

The patent was issued to two inventors, Dr. Ulf-Hakan Stenman,of Helsinki University Central Hospital, and Dr. Hans Lilja, ofLund University.

The inventors gave exclusive rights to Wallac, which subsequentlygranted a sublicense to Abbott. The patent covers immmunoassaysfor free PSA and the use of the ratio of free-to-total PSA tobetter distinguish between prostate cancer and benign prostatichyperplasia (BPH).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Related Content